Tag
Tozorakimab, targeting interleukin-33, significantly reduces moderate to severe COPD exacerbations in former and current smokers despite standard inhaled therapy, offering a novel therapeutic approach with a favorable safety profile.
This phase 3 trial demonstrates that clesrovimab, a long-acting monoclonal antibody, is safe and well-tolerated in infants at risk for severe RSV disease across two consecutive RSV seasons, supporting its role in extended RSV prophylaxis.
The phase 2 AMULET trial evaluated amlenetug, an anti-α-synuclein monoclonal antibody, in MSA patients. While it did not meet its primary endpoint, the antibody showed a non-significant 19% slowing of disease progression with an acceptable
This review synthesizes evidence on MAM01, a monoclonal antibody targeting Plasmodium falciparum circumsporozoite protein, summarizing its first-in-human phase 1 trial demonstrating safety and protective efficacy, alongside contextual advan
Post hoc analysis of the MELODY Phase 3 trial shows nirsevimab reduced RSV-associated lower respiratory tract infections and RSV coinfections in healthy term and late-preterm infants, with no signal of viral replacement by other respiratory
A single dose of clesrovimab significantly reduces respiratory syncytial virus (RSV) infections and hospitalizations in healthy infants during their first RSV season, with a safety profile comparable to placebo.
Cendakimab, a monoclonal antibody targeting IL-13, shows significant improvements in symptoms, histologic response, and endoscopic features in eosinophilic esophagitis, with a tolerable safety profile through 48 weeks.
A phase 4 randomized trial demonstrates that combining rabies monoclonal antibody with vaccine in category 3 exposures is safe, immunogenic, and effective in preventing rabies up to one year post-exposure.
A phase 3 trial shows inebilizumab, a CD19+ B-cell depleting antibody, improves function and reduces disease severity in generalized myasthenia gravis without increasing serious adverse events.
